O1016
OPC-21268 hydrate
≥98% (HPLC)
别名:
1-{1-[4(3-acetylaminopropoxy)benzoyl]-4-piperidyl}-3,4-dihydro-2(1H)-quinolinone hydrate, N-[3-[4-[[4-(3,4-dihydro-2-oxo-1(2H)-quinolinyl)-1-piperidinyl]carbonyl]phenoxy]propyl]-acetamide hydrate
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C26H31N3O4 · xH2O
化学文摘社编号:
分子量:
449.54 (anhydrous basis)
MDL编号:
UNSPSC代码:
51111800
PubChem化学物质编号:
NACRES:
NA.77
方案
≥98% (HPLC)
表单
powder
颜色
white to off-white
溶解性
DMSO: ≥20 mg/mL
创始人
Merck & Co., Inc., Kenilworth, NJ, U.S.
储存温度
2-8°C
SMILES字符串
O.CC(=O)NCCCOc1ccc(cc1)C(=O)N2CCC(CC2)N3C(=O)CCc4ccccc34
InChI
1S/C26H31N3O4.H2O/c1-19(30)27-15-4-18-33-23-10-7-21(8-11-23)26(32)28-16-13-22(14-17-28)29-24-6-3-2-5-20(24)9-12-25(29)31;/h2-3,5-8,10-11,22H,4,9,12-18H2,1H3,(H,27,30);1H2
InChI key
QTCWOUIERWBMQV-UHFFFAOYSA-N
生化/生理作用
OPC-21268 is a vasopressin V1a selective antagonist.
OPC-21268 is one of 2 non-peptide V1a selective antagonists, along with SR-49059. Arginine vasopressin (AVP) is a hormone that plays an important part in circulatory and water homoeostasis and is important in renal hemodynamic alterations, water retention, and cardiac remodeling in congestive heart failure (CHF). There are three AVP receptor subtypes-V1a, V1b, and V2 - all belong to the large rhodopsin-like G-protein-coupled receptor family. V(1a) antagonists improve water balance and cardiac hypertrophy in CHF and might be beneficial for the treatment of water retention and cardiac remodeling in CHF.
特点和优势
This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
警示用语：
Warning
危险声明
危险分类
Acute Tox. 4 Oral - Aquatic Acute 1
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
此项目有
C Serradeil-Le Gal et al.
Progress in brain research, 139, 197-210 (2002-11-20)
The involvement of vasopressin (AVP) in several pathological states has been reported recently and the selective blockade of the different AVP receptors could offer new clinical perspectives. During the past few years, various selective, orally active AVP V1a (OPC-21268, SR49059
[Renal action of vasopressin].
Masami Sasaki et al.
Nihon rinsho. Japanese journal of clinical medicine, 64 Suppl 2, 257-264 (2006-03-10)
A B Roald et al.
Acta physiologica Scandinavica, 182(2), 197-204 (2004-09-29)
Arginine vasopressin (AVP) might influence urinary concentration ability by altering the intrarenal distribution of glomerular filtration rate (GFR). To study this possibility we have measured the intracortical distribution of GFR following acute AVP-V1 receptor stimulation in anaesthetized female Sprague-Dawley (SPD)
A E Bogolepova
Zhurnal evoliutsionnoi biokhimii i fiziologii, 47(1), 49-53 (2011-04-08)
Active transport of sodium ions across the isolated abdominal skin of the frog Rana temporaria after application of arginine-vasotocin (AVT) and 1-deamino-arginine-vasotocin (1dAVT) was studied by measurement of the short-circuit current (SCC). The maximal increase in the SCC values (26
Tatjana A Karavashkina et al.
General and comparative endocrinology, 170(3), 460-467 (2010-11-06)
1-Deamino-arginine vasotocin (1dAVT) induced diuresis and a considerable increase in urinary sodium excretion in female Wistar rats. Sodium fractional excretion rose up to 19.3 ± 1.1%. An increase in urine flow rate after 1dAVT (0.5 nmol/kg body-weight [bw]) injection was
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持